COVID-19 - National Guidance for Healthcare Providers
Addendum to the guidance on the use of COVID-19 vaccines in the fall of 2023. National Advisory Committee on Immunization. 12 September 2023.
Summary of National Advisory Committee on Immunization (NACI) Supplemental Statement of September 12, 2023: Addendum to the guidance on the use of COVID-19 vaccines in the fall of 2023. National Advisory Committee on Immunization. 12 September 2023.
Guidance on the use of COVID-19 vaccines in the fall of 2023. National Advisory Committee on Immunization. 11 July 2023.
Summary of National Advisory Committee on Immunization (NACI) Statement of July 11, 2023: Guidance on the use of COVID-19 vaccines in the fall of 2023. National Advisory Committee on Immunization. 11 July 2023.
Interim guidance on the use of bivalent Omicron-containing COVID-19 vaccines for primary series. National Advisory Committee on Immunization (NACI). 09 June 2023.
Summary of National Advisory Committee on Immunization (NACI) Statement of June 9, 2023: Interim guidance on the use of bivalent Omicron-containing COVID-19 vaccines for primary series. National Advisory Committee on Immunization (NACI). 09 June 2023.
Interim guidance on the use of bivalent Omicron-containing COVID-19 vaccines for primary series. National Advisory Committee on Immunization (NACI). 09 June 2023.
COVID-19 vaccine: Canadian Immunization Guide. Public Health Agency of Canada. Updated 22 March 2023.
Guidance on an additional COVID-19 booster dose in the spring of 2023 for individuals at high risk of severe illness due to COVID-19. National Advisory Committee on Immunization. 03 March 2023.
Summary of National Advisory Committee on Immunization (NACI) Statement of March 3, 2023: Guidance on an additional COVID-19 booster dose in the spring of 2023 for individuals at high risk of severe illness due to COVID-19. National Advisory Committee on Immunization (NACI). 03 March 2023.
Guidance on COVID-19 vaccine booster doses: Initial considerations for 2023. National Advisory Committee on Immunization. 20 January 2023.
Summary of National Advisory Committee on Immunization (NACI) Statement of January 20, 2023: Guidance on COVID-19 vaccine booster doses: Initial considerations for 2023. National Advisory Committee on Immunization. 20 January 2023.
Updated recommendations on the use of COVID-19 vaccine booster doses in children 5 to 11 years of age and concurrent vaccine administration. National Advisory Committee on Immunization. 09 December 2022.
Summary of National Advisory Committee on Immunization (NACI) Statement of December 9, 2022: Updated recommendations on the use of COVID-19 vaccine booster doses in children 5 to 11 years of age and concurrent vaccine administration. National Advisory Committee on Immunization. 09 December 2022.
Summary of National Advisory Committee on Immunization (NACI) updates of November 3, 2022: Recommendations on the use of Moderna Spikevax BA.4/5 bivalent mRNA (50 mcg) COVID-19 booster vaccine in adults. National Advisory Committee on Immunization. 03 November 2022.
Recommendations on the use of Pfizer-BioNTech Comirnaty (3 mcg) COVID-19 vaccine in children 6 months to 4 years of age. National Advisory Committee on Immunization. 21 October 2022.
Summary of National Advisory Committee on Immunization (NACI) Statement of October 21, 2022: Recommendations on the use of Pfizer-BioNTech Comirnaty (3 mcg) COVID-19 vaccine in children 6 months to 4 years of age. National Advisory Committee on Immunization. 21 October 2022.
Updated guidance on COVID-19 vaccine booster doses in Canada. 07 National Advisory Committee on Immunization. 07 October 2022.
Summary of National Advisory Committee on Immunization (NACI) Statement of October 7, 2022: Updated guidance on COVID-19 vaccine booster doses in Canada. National Advisory Committee on Immunization. 07 October 2022.
Updated guidance on COVID-19 vaccines for individuals who are pregnant or breastfeeding. National Advisory Committee on Immunization. 09 September 2022.
Summary of National Advisory Committee on Immunization (NACI) Statement of September 9, 2022: Updated guidance on COVID-19 vaccines for individuals who are pregnant or breastfeeding. National Advisory Committee on Immunization. 09 September 2022.
Recommendations on the use of bivalent Omicron-containing mRNA COVID-19 vaccines. National Advisory Committee on Immunization. 01 September 2022.
Summary of National Advisory Committee on Immunization (NACI) Statement of September 1, 2022: Recommendations on the use of bivalent Omicron-containing mRNA COVID-19 vaccines. National Advisory Committee on Immunization. 01 September 2022.
Summary of National Advisory Committee on Immunization (NACI) Statement of August 19, 2022: Recommendations on the use of a first booster dose of Pfizer-BioNTech Comirnaty COVID-19 vaccine in children 5 to 11 years of age. National Advisory Committee on Immunization. 19 August 2022.
Recommendations on the use of Moderna Spikevax COVID-19 vaccine in children 6 months to 5 years of age. National Advisory Committee on Immunization. 14 July 2022.
Summary of National Advisory Committee on Immunization (NACI) Statement of July 14, 2022: Recommendations on the use of Moderna Spikevax COVID-19 vaccine in children 6 months to 5 years of age. National Advisory Committee on Immunization. 14 July 2022.
Statement: Health Canada authorizes use of Moderna COVID-19 vaccine in children 6 months to 5 years of age. Health Canada. 14 July 2022.
Interim guidance on planning considerations for a fall 2022 COVID-19 vaccine booster program in Canada. National Advisory Committee on Immunization. 29 June 2022.
Summary of National Advisory Committee (NACI) Statement of June 29, 2022: Interim guidance on planning considerations for a fall 2022 COVID-19 vaccine booster program in Canada. National Advisory Committee on Immunization. 29 June 2022.
Summary of updates in the Canadian Immunization Guide of June 21, 2022: Updated guidance on COVID-19 vaccines in Canada. National Advisory Committee on Immunization. 21 June 2022.
Updated guidance on a first booster dose of COVID-19 vaccines in Canada. National Advisory Committee on Immunization. 12 April 2022.
Summary of National Advisory Committee on Immunization (NACI) Statement of April 12, 2022: Updated guidance on a first booster dose of COVID-19 vaccines in Canada. National Advisory Committee on Immunization. 12 April 2022.
Initial guidance on a second booster dose of COVID-19 vaccines in Canada. National Advisory Committee on Immunization. 05 April 2022.
Summary of National Advisory Committee on Immunization (NACI) Statement of April 5, 2022: Initial guidance on a second booster dose of COVID-19 vaccine in Canada. National Advisory Committee on Immunization. 05 April 2022.
Recommendations on the use of Moderna Spikevax COVID-19 vaccine in children 6 to 11 years of age. National Advisory Committee on Immunization. 17 March 2022.
Summary of National Advisory Committee on Immunization (NACI) Statement of March 17, 2022: Recommendations on the use of Moderna Spikevax COVID-19 vaccine in children 6 to 11 years of age. National Advisory Committee on Immunization. 17 March 2022.
Recommendations on the use of Medicago COVID-19 vaccine (Covifenz). National Advisory Committee on Immunization (NACI). 11 March 2022.
COVID-19: Recommendations for those vaccinated with vaccines not authorized by Health Canada for those staying in Canada to live, work or study. Public Health Agency of Canada. 11 March 2022.
Recommendations on the use of Novavax Nuvaxovid COVID-19 vaccine. National Advisory Committee on Immunization (NACI). 17 February 2022.
Summary of National Advisory Committee on Immunization (NACI) Statement of February 17, 2022: Recommendations on the use of Novavax Nuvaxovid COVID-19 vaccine. National Advisory Committee on Immunization. 17 February 2022.
COVID-19 vaccine: Canadian Immunization Guide. Government of Canada. 09 February 2022.
Rapid response: Updated guidance on COVID-19 vaccination timing for individuals previously infected with SARS-CoV-2. National Advisory Committee on Immunization (NACI). 04 February 2022.
Summary of National Advisory Committee on Immunization Rapid Response of February 4, 2022. National Advisory Committee on Immunization (NACI). 04 February 2022.
Rapid response: Guidance on the use of booster COVID-19 vaccine doses in adolescents 12-17 years of age. National Advisory Committee on Immunization (NACI). 28 January 2022.
Summary of National Advisory Committee on Immunization Rapid Response of January 28, 2022. National Advisory Committee on Immunization (NACI). 28 January 2022.
Updated recommendations on the use of COVID-19 vaccines in children 5 to 11 years of age. National Advisory Committee on Immunization (NACI). 25 January 2022.
Summary of National Advisory Committee on Immunization Statement of January 25, 2022 – Updated recommendations on the use of COVID-19 vaccines in children 5 to 11 years of age. National Advisory Committee on Immunization (NACI). 25 January 2022.
Summary of NACI advice on vaccination with COVID-19 vaccines following myocarditis (with or without pericarditis). National Advisory Committee on Immunization (NACI). 14 January 2022.
Guidance on booster COVID-19 vaccine doses in Canada – Update December 3, 2021. 03 December 2021. National Advisory Committee on Immunization.
Summary of the National Advisory Committee on Immunization (NACI) Statement of December 3, 2021. 03 December 2021. National Advisory Committee on Immunization.
Rapid response: Updated recommendation on the use of authorized COVID-19 vaccines in individuals aged 12 years and older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccines. 03 December 2021. National Advisory Committee on Immunization.
Summary of the National Advisory Committee on Immunization (NACI) Rapid Response of December 3, 2021. 03 December 2021. National Advisory Committee on Immunization.
Recommendation on the use of the Pfizer-BioNTech COVID-19 vaccine (10 mcg) in children 5-11 years of age. 19 November 2021. National Advisory Committee on Immunization.
Summary of the National Advisory Committee on Immunization (NACI) Statement of November 19, 2021 – Recommendation on the use of the Pfizer-BioNTech COVID-19 vaccine (10 mcg) in children 5-11 years of age. 19 November 2021. National Advisory Committee on Immunization.
Interim guidance on booster COVID-19 vaccine doses in Canada. 29 October 2021. National Advisory Committee on Immunization.
Summary of National Advisory Committee on Immunization (NACI) Statement: Interim guidance on booster COVID-19 vaccine doses in Canada. 29 October 2021. National Advisory Committee on Immunization.
Recommendations on the use of COVID-19 vaccines. 22 October 2021. National Advisory Committee on Immunization.
Summary of National Advisory Committee on Immunization (NACI) statement: Recommendations on the use of COVID-19 vaccines – update: October 22, 2021. National Advisory Committee on Immunization.
Quick reference guide on use of COVID-19 vaccines: Overview. 13 October 2021. Public Health Agency of Canada.
National Advisory Committee on Immunization (NACI) rapid response: Booster dose in long-term care residents and seniors living in other congregate settings. 28 September 2021. National Advisory Committee on Immunization.
Summary of National Advisory Committee on Immunization (NACI) rapid response: Booster dose of COVID-19 vaccine in long-term care residents and seniors living in other congregate settings. 28 September 2021. National Advisory Committee on Immunization.
National Advisory Committee on Immunization (NACI) rapid response: Additional dose of COVID-19 vaccine in immunocompromised individuals following 1- or 2- dose primary series. 10 September 2021. National Advisory Committee on Immunization.
Summary of National Advisory Committee on Immunization (NACI) rapid response: Additional dose of COVID-19 vaccine in immunocompromised individuals following a 1- or 2-dose primary series. 10 September 2021. National Advisory Committee on Immunization.
Recommendation on the use of mRNA COVID-19 vaccines in adolescents 12 to 17 years of age. 27 August 2021. National Advisory Committee on Immunization.
COVID-19 Recommendations for those vaccinated with vaccines not authorized by Health Canada for those staying in Canada to live, work or study. 17 August 2021. Government of Canada.
Guidance for Health Care Leaders During the Recovery Stage of the COVID-19 Pandemic: A Consensus Statement. JAMA Network Open. 08 July 2021.
NACI Rapid Response: Interchangeability of authorized COVID-19 vaccines. 01 June 2021. National Advisory Committee on Immunization.
Summary of NACI Rapid Response of June 1, 2021. National Advisory Committee on Immunization.
Use of Pfizer-BioNTech COVID-19 vaccine in adolescents 12-18 years of age. National Advisory Committee on Immunization.
Summary of National Advisory Committee on Immunization Statement of May 18, 2021. National Advisory Committee on Immunization.
Extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada in the context of limited vaccine supply. 07 April 2021. National Advisory Committee on Immunization.
Summary of NACI extended dose intervals statement of April 7, 2021. National Advisory Committee on Immunization.
COVID-19 in Canada: A one-year update on social and economic impacts. 11 March 2021. Statistics Canada.
Guidance on the prioritization of initial doses of COVID-19 vaccine(s). National Advisory Committee on Immunization.
Interim guidance on continuity of immunization programs during the COVID-19 pandemic. National Advisory Committee on Immunization.
Recommendations on the use of COVID-19 vaccines. National Advisory Committee on Immunization.
Preliminary guidance on key populations for early COVID-19 immunization. National Advisory Committee on Immunization.
Planning guidance for administration of COVID-19 vaccine. National Advisory Committee on Immunization.
Planning guidance for immunization clinics for COVID-19 vaccines. National Advisory Committee on Immunization.
Vaccines and treatments for COVID-19: Vaccine rollout. Government of Canada.
Coronavirus disease: Guidance documents. Government of Canada.
The National Collaborating Centre for Methods and Tools’ planned COVID-19 response in 2021. National Collaborating Centre for Methods and Tools (NCCMT).